Samsung Biologics Announces Strategic Alliance on Biopharmaceutical Manufacturing with Merck Millipore. 

​(August 20, 2014) – Samsung BioLogis announced today that Samsung Biologics and Merck Millipore signed an MOU (Memorandum of Understanding) for a strategic alliance on the biopharmaceutical business. The alliance is intended to encompass a long-term supply agreement in which Merck Millipore will provide raw materials for biopharmaceutical manufacturing.

Dr. Udit Batra, President and CEO of Merck Millipore, and Benoit Gourdier, head of Merck Millipore’s Process Solutions Asia, were present at the signing ceremony held at Samsung Biologics’ headquarters in Korea. “Our latest partnership in the biopharmaceutical sector will further strengthen the great relationship Merck and Samsung have built in other business areas for the past years. It will also help us support Samsung’s initiative in the CMO and biopharmaceutical field,” said Dr. Batra.

Merck will become an essential raw material supplier for Samsung Biologics’ 30KL facility as well as its new 150KL new facility that is expected to be completed in 2015 at Songdo, Incheon, Korea.

“Samsung Biologics is delighted to develop a strategic alliance with Merck, which will not only provide us a stable supply of crucial raw materials but also bring mutual advantages for both companies’ long-term business strategies and competitiveness in the biopharmaceutical industry,” said Dr. TH Kim, President and CEO of Samsung Biologics.


About Samsung Biologics
Samsung Biologics is a global full-service provider of quality-driven contract process development and CGMP manufacturing to the global biopharmaceutical industry. Our facilities are custom designed for monoclonal & recombinant production with maximum flexibility. Our one-stop services include cell line generation, process and analytical method development, analytical services, clinical and commercial bulk CGMP manufacturing of drug substance and drug product including quality assurance, quality control, regulatory compliance standards & support for our customers. For additional information about the company, please visit http://www.Samsung Biologics.com.

About Merck
Merck is a leading company for innovative and top-quality high-tech products in the pharmaceutical and chemical sectors. With its four divisions Merck Serono, Consumer Health, Performance Materials and Merck Millipore, Merck generated total revenues of € 11.1 billion in 2013. Around 38,000 Merck employees work in 66 countries to improve the quality of life for patients, to further the success of customers and to help meet global challenges. Merck is the world’s oldest pharmaceutical and chemical company – since 1668, the company has stood for innovation, business success and responsible entrepreneurship. Holding an approximately 70 percent interest, the founding family remains the majority owner of the company to this day. Merck, Darmstadt, Germany is holding the global rights to the Merck name and brand. The only exceptions are Canada and the United States, where the company is known as EMD.

About Merck Millipore
Merck Millipore is the Life Science division of Merck KGaA of Germany and offers a broad range of innovative, performance products, services and business relationships that enable our customers’ success in research, development and production of biotech and pharmaceutical drug therapies. Through dedicated collaboration on new scientific and engineering insights, and as one of the top three R&D investors in the Life Science Tools industry, Merck Millipore serves as a strategic partner to customers and helps advance the promise of life science.
Headquartered in Billerica, Massachusetts, the division has around 10,000 employees, operations in 66 countries and 2013 revenues of € 2.6 billion. Merck Millipore operates as EMD Millipore in the U.S. and Canada. 

Note: Merck KGaA or Merck shall mean Merck KGaA, Darmstadt, Germany.